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Short Report 
Nebulized colistin causes chest tightness in adults with 
cystic fibrosis 
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Introduction 
Nebulized antipseudomonal antibiotics may be use- 
ful therapeutic agents in patients with cystic fibrosis 
(CF) (l-3). Short term studies of nebulized colistin 
have demonstrated its efficacy in eradicating recently 
acquired Pseudomonas aeruginosa in children (4) and 
in the management of chronic infection in adults (5). 
There is no uniform policy regarding the use of 
nebulized colistin in different CF centres. In our unit 
patients infected with P. aeruginosa are candidates for 
regular therapy with the drug if their requirements for 
oral or i.v. antibiotics are increasing and their pulmon- 
ary function is deteriorating. Each potential candidate 
is challenged to a standard dose of nebulized colistin 
and, if immediate side effects are not prohibitive, com- 
mences regular therapy with the drug. In stable state 
we recommend that patients inhale nebulized colistin 
twicedaily, butduringexacerbationsrequiringi.v. anti- 
biotics that the drug be omitted. We do not use the drug 
as first line therapy during infective exacerbations. 
Nebulized colistin causes chest tightness in some 
patients and may lead to discontinuation of regular 
therapy (4). In this study we have focused specifically on 
chest tightness as a reason for discontinuing therapy. 
Patients able to maintain regular therapy (tolerant) 
have been compared to those who discontinued or 
could not begin regular therapy because of chest tight- 
ness (intolerant) using three measurements; the degree 
of bronchoconstriction at colistin challenge, severity of 
airways disease (% predicted FEV,) and reversibility 
to bronchodilators in stable state. 
Patients and Methods 
Forty-six patients with CF (24 male, 22 female), 
mean age 20.7 years (range 15-35), mean FEV, 51% 
predicted (range 18-l 15), chronically infected with P. 
aeruginosa were challenged to nebulized colistin before 
Received 8 April 1992 and accepted in revised form 22 October 1992. 
*To whom correspondence should be addressed. 
0954-6 1 I I /94/020 I45 + 03 $08.00/O 
beginning regular therapy with the drug. The challenge 
was performed when each patient was clinically stable. 
It is normal practice to administer nebulized anti- 
biotics after chest clearance. Therefore prior to colistin 
challenge each patient received their routine nebulized 
bronchodilator followed by chest physiotherapy. 
Physiotherapy was individualized for each patient and 
consisted of the active cycle of breathing techniques, 
incorporating the forced expiration technique in 
gravity assisted positions. When clinically stable, 20- 
30 min is usually sufficient for the majority of patients 
to achieve chest clearance. Immediately after physio- 
therapy was completed, spirometry was performed 
using a dry bellows spirometer (Vitalograph) and the 
recorded baseline FEV, and FVC were expressed as 
percentages of predicted values. 
Two million units of Colistin Sulphomethate 
Sodium BP dissolved in 4 ml of 0.9% sodium chloride 
were then administered to each patient in an Inspiron 
mini-nebulizer driven by a CR60 compressor (Medic 
Aid). After colistin challenge, the spirometric 
measurements were repeated at 0, 15 and 30min. 
Changes in spirometry were expressed as follows: 
% Change in FEV, = 
Maximum change in FEV, x 100 
Baseline FEV, 
On a separate occasion each patient had been 
assessed for maximum reversibility to nebulized 
bronchodilators while in stable clinical state. Patients 
were considered to be reversible if their rise in FEV, 
was greater than 15% and irreversible if their rise in 
FEV, was less than 15%. 
Statistical analysis utilized the unpaired t-test and 
the x2 analysis. 
Results 
TIMING OF BRONCHOCONSTRICTION TO COLISTIN 
Thirty-five of the 46 patients developed a broncho- 
constrictor response to colistin. The maximum 
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Fig. I The relationship between the severity of airways 
disease and the maximum % change in FEV, to colistin chal- 
lenge in tolerant and intolerant patients. r=0.42, P=O.Ol~ 
x = tolerant patient. 0 = intolerant patient. 
bronchoconstrictor response was measured immedi- 
ately after administration in 30 patients, 15 min later in 
three patients, and 30 min after completion of nebuliz- 
ation in two patients. There was no change in FEV, in 
seven patients and a bronchodilator response in four. 
AIRWAYS DISEASE SEVERITY AND 
BRONCHOCONSTRICTION TO COLISTIN 
There was a statistically significant correlation 
between severity of airways disease (% predicted 
FEV,) and the maximum percentage change in FEV, 
to colistin challenge r = 0.42 P= 0.01 (Fig. 1). 
TOLERANCE OF NEBULIZED COLISTIN 
Fifteen of the 46 patients could not tolerate 
nebulizsd colistin because of chest tightness. Two of 
those patients were not prescribed colistin because at 
the time of challenge they developed severe chest tight- 
ness (falls in FEV, 33% and 25%). Those who stopped 
colistin therapy because of chest tightness had a sig- 
nificantly greater mean % fall in FEV, (16%) at the 
time of colistin challenge than those who continued 
treatment (7%) P=O.O02. 
SEVERITY OF AIRWAYS DISEASE AND TOLERANCE/ 
INTOLERANCE OF NEBULIZED COLISTIN 
The mean % predicted FEV, in patients tolerant of 
colistin (56.8) was significantly greater than the mean 
% predicted FEV, in patients intolerant of the drug 
(41.4) P=O.O2 (Fig. 2). 
REVERSIBILITY TO BRONCHODILATORS AND TOLERANCE 
OF COLISTIN 
Fourteen patients had reversible and 3 1 irreversible 
airways to bronchodilators. Data for one patient was 
not available and she was excluded from the analysis. 
There was no significant difference between the mean 
baseline FEV, % predicted of patients with reversible 
airways (44%) and those with irreversible airways 
(54%) P=O.l. 
No significant difference was observed between the 
mean maximum % fall in FEV, to colistin in those with 
reversible airways (8%) and those with irreversible air- 
ways (I I %) P = 0.24. There was no significant differ- 
ence between the proportion of reversible patients in 
the groups tolerant (4/15) and intolerant (10/30) of 
nebulized colistin P= 0.37. 
Discussion 
Our results have confirmed that a significant 
number of adults with CF (32%) are intolerant of 
nebulized colistin because of chest tightness. Although 
the mean FEV, % predicted of the patients intolerant 
of colistin was significantly lower than the mean FEV, 
% predicted of those who tolerated the drug, our 
results (Fig. 2) illustrate that there is no distinct cut off 
between the two groups. Hence, no individual should 
be precluded from a trial of nebulized colistin because 
their FEV, is low. 
In this study we have used maximum airways reversi- 
bility to bronchodilators as a measure of airways 
lability. For any individual with CF, bronchodilator 
reversibility may vary between infective exacerbation 
and stable state and may also change with progression 
of disease (6). We assessed airways lability under the 
conditions in which colistin is used by the patients; 
bronchodilator reversibility was measured in stable 
state and within weeks of colistin challenge. We were 
unable to demonstrate any difference between the pro- 
portionofreversiblepatientsinthegroupwho tolerated 
colistin and the group intolerant of the drug. However 
bronchodilator reversibility may be an insensitive 
measure of airways lability. In one series only seven 
from 20 CF patients demonstrated to have bronchial 
hyperredctivity were reversible to bronchodilators (7). 
There is evidence to suggest that heightened bronchial 
reactivity in CF reflects severity of underlying lung 
disease (7) although other studies have failed to con- 
firm these findings (8). To measure bronchial hyper- 
reactivity a measure of decrease in FEV, from its 
baseline is expressed in percentage form. The validity 
of measuring a percentage fall from an abnormal base- 
line is open to debate. Furthermore, resistance to 
laminar flow through tubes is inversely proportional to 
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% predicted, mean SD) of patients tolerant of colistin 56.8 (24) and 
the fourth square of the radius. Hence a reduction in 
the calibre of a constricted airway will produce a 
proportionately greater increase in airflow resistance 
than a similar reduction in an airway of greater 
diameter. For these reasons an apparent relationship 
between increasing bronchial hyperreactivity and air- 
ways severity is difficult to validate. In our study we 
demonstrated a linear relationship between baseline 
FEV, % predicted and % change in FEV, at 
colistin challenge. For the same reasons, the signifi- 
cance of the association is difficult to assess. However, 
it is possible that the greater tendency towards 
bronchoconstriction in patients with lower baseline 
FEV,s could be explained by greater bronchial hyper- 
reactivity. This issue should be addressed in future 
studies. 
For patients who are intolerant of colistin because 
of chest tightness it may be possible to continue ther- 
apy by reducing the dose and concentration of the 
nebulized drug. 
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